Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
As we have previously discussed, the question posed above is a highly controversial one, and there is a legal case in the U.S. — the case challenging Myriad Genetics ownership of patents on the BRCA1 and BRCA2 genes for specific types of breast cancer — which has now reached the Supreme Court (sometimes called SCOTUS [...]
Filed under: Diagnosis, Risk | Tagged: gene, Myriad Genetics, patent, Supreme Court | 3 Comments »
In March 2010, as previously reported on this web site, a federal court judge initially ruled that the patents on the BRCA1 and BRCA2 genes held by Myriad Genetics and the University of Utah “are directed to a law of nature and were therefore improperly granted.”
Filed under: Diagnosis, Management | Tagged: BRCA, gene, Myriad Genetics, patent | 1 Comment »
In a case that has major ramifications for the health care industry and for personalized medicine, a federal judge in New York yesterday invalidated the patents on BRAC1 and BRAC2 genes held by Myriad Genetics and the University of Utah.
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: gene, patent, test | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site